Name | Cinanserin hydrochloride |
Description | Cinanserin hydrochloride (SQ 10643), a high-affinity antagonist of the 5-HT2 receptor (Ki: 41 nM), is also a 3C-like protease inhibitor of severe acute respiratory syndrome coronavirus. |
In vitro | Cinanserin and Cinanserin hydrochloride inhibit the catalytic activity of SARS-CoV 3CLpro and HCoV-229E 3CLpro (IC50: 4.68 μM and 5.68 μM). Cinanserin/Cinanserin hydrochloride has a binding affinity to SARS-CoV 3CLpro, HCoV-229E 3CLpro, with the KD values of 49.4 μM/78.0 μM for SARS-associated coronavirus (SARS-CoV) 3CLpro[1]. |
In vivo | Cinanserin (5 mg/kg; intravenous injection; 2 hours; male Wistar rats) treatment significantly reduces systemic burn edema to shamburn levels[2]. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 125 mg/mL (331.62 mM), Sonication is recommended. H2O : 100 mg/mL (265.29 mM), Sonication is recommended.
|
Keywords | edema | replication | Serotonin Receptor | Cinanserin hydrochloride | leukocyte | virus | burn | 3C-like | Cinanserin Hydrochloride | proteinase | endothelial | Influenza Virus | Cinanserin | SQ-10643 | Inhibitor | 5-hydroxytryptamine Receptor | systemic | 5-HT Receptor | inhibit | 5-HT2 | SQ10643 |
Inhibitors Related | Rifampicin | Alverine citrate | Acetylcysteine | Dapoxetine hydrochloride | α-Vitamin E | Nitazoxanide | Curcumin | N-Acetylneuraminic acid | Naringenin | Salcomine | Crystal Violet | β-Cyclodextrin |
Related Compound Libraries | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Pain-Related Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | Anti-Viral Compound Library | Inhibitor Library | Bioactive Compounds Library Max | GPCR Compound Library | Serotonin Receptor-Targeted Compound Library |